Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus DECADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus DECADERM.
CORTAN vs DECADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid